TWI868051B - 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 - Google Patents

與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 Download PDF

Info

Publication number
TWI868051B
TWI868051B TW107120839A TW107120839A TWI868051B TW I868051 B TWI868051 B TW I868051B TW 107120839 A TW107120839 A TW 107120839A TW 107120839 A TW107120839 A TW 107120839A TW I868051 B TWI868051 B TW I868051B
Authority
TW
Taiwan
Prior art keywords
disease
fibrinolysinogen
pai
overexpression
bleomycin
Prior art date
Application number
TW107120839A
Other languages
English (en)
Chinese (zh)
Other versions
TW201904990A (zh
Inventor
萊恩 加格諾
布萊吉特 格洛克斯
皮爾瑞 拉瑞琳
Original Assignee
美商波麥堤克生物治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商波麥堤克生物治療股份有限公司 filed Critical 美商波麥堤克生物治療股份有限公司
Publication of TW201904990A publication Critical patent/TW201904990A/zh
Application granted granted Critical
Publication of TWI868051B publication Critical patent/TWI868051B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107120839A 2017-06-23 2018-06-15 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 TWI868051B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23

Publications (2)

Publication Number Publication Date
TW201904990A TW201904990A (zh) 2019-02-01
TWI868051B true TWI868051B (zh) 2025-01-01

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107120839A TWI868051B (zh) 2017-06-23 2018-06-15 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI787732B (zh) * 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
CN115666625A (zh) * 2020-03-24 2023-01-31 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
US20230173039A1 (en) * 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
KR20220158036A (ko) * 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
BR112016002753A2 (pt) * 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
TW201722464A (zh) 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CA3047170A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
JP7168990B2 (ja) * 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Also Published As

Publication number Publication date
IL271470A (en) 2020-01-30
WO2018234861A1 (en) 2018-12-27
EP3641888A4 (en) 2021-03-10
AU2018287316A1 (en) 2020-02-06
DK3641888T3 (da) 2024-01-02
EP3641888B1 (en) 2023-10-11
NZ760921A (en) 2026-01-30
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
US20210330761A1 (en) 2021-10-28
CN110831668A (zh) 2020-02-21
AU2018287316B2 (en) 2024-09-19
KR20200019217A (ko) 2020-02-21
EP3641888A1 (en) 2020-04-29
ZA202000280B (en) 2021-08-25
CN110831668B (zh) 2024-04-12
MY203136A (en) 2024-06-10
TW201904990A (zh) 2019-02-01
IL271470B2 (en) 2025-07-01
CA3068153A1 (en) 2018-12-27
SG11201912813SA (en) 2020-01-30
IL271470B1 (en) 2025-03-01
RU2020100080A3 (enExample) 2021-11-02
RU2020100080A (ru) 2021-07-23
ES2965937T3 (es) 2024-04-17
MX2019015741A (es) 2020-11-11
JP2020524689A (ja) 2020-08-20
CL2019003789A1 (es) 2020-07-10
BR112019027229A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
CN110831668B (zh) 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗
Ji et al. An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity
RU2662564C2 (ru) Лечение воспалительных заболеваний кожи
Zeng et al. Paeoniflorin of Paeonia lactiflora prevents renal interstitial fibrosis induced by unilateral ureteral obstruction in mice
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
Zhu et al. MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity
JP4351041B2 (ja) 傷治癒のための処置および組成物
JP2004532892A6 (ja) 傷治癒のための処置および組成物
CA3068637A1 (en) Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents
JP6535036B2 (ja) 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物
KR20180070708A (ko) 상처 치유를 위한 플라스미노겐 투여 요법
US11766467B2 (en) Methods of treating wounds using cathepsin K inhibitors
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
Jitsuiki et al. A case of blue rubber bleb nevus syndrome with Kasabach-Merritt syndrome and heart failure
JP6289511B2 (ja) 羊水塞栓の治療剤
US20260014132A1 (en) Protease activated receptor 2 (par2) inhibitor and its uses
US20240199703A1 (en) Procoagulant peptides and use thereof
TW202002954A (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
HK1065719B (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
HK1065719A1 (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers